Izotropic Corp. (TSE:IZO)
:IZO
Want to see TSE:IZO full AI Analyst Report?
Top Page
Izotropic
(IZO)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.30
▲(7.50% Upside)
Action:ReiteratedDate:04/29/26
The score is primarily weighed down by weak financial performance (no revenue, continued losses, negative equity, and ongoing cash burn). Technicals provide some support due to price strength above major moving averages and a positive MACD, but overbought RSI/Stoch reduce confidence in near-term sustainability. Valuation remains challenged given the negative P/E and no indicated dividend yield.
Positive Factors
Product Differentiation
Izoview's core product is a dedicated breast CT system designed to improve screening, diagnosis and workflow versus conventional mammography. A focused, clinically differentiated device can create durable competitive advantage via clinical utility, workflow integration and IP if commercialized.
Negative Factors
No Revenue / Pre‑commercial
The company reports no revenue and a negative gross profit, indicating its core product is not commercially generating sales. This structural lack of revenue forces dependence on external capital, leaves adoption unproven, and delays the path to sustained free cash flow and profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Product Differentiation
Izoview's core product is a dedicated breast CT system designed to improve screening, diagnosis and workflow versus conventional mammography. A focused, clinically differentiated device can create durable competitive advantage via clinical utility, workflow integration and IP if commercialized.
Read all positive factors
Izotropic (IZO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$21.73M
Dividend YieldN/A
Average Volume (3M)43.33K
Price to Earnings (P/E)―
Beta (1Y)-0.19
Revenue GrowthN/A
EPS Growth-7.34%
CountryCA
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding68,984,680
10 Day Avg. Volume24,438
30 Day Avg. Volume43,328
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-2.90
Price to Sales (P/S)0.00
P/FCF Ratio-22.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Izotropic Business Overview & Revenue Model
Company Description
Izotropic Corporation, a MedTech company, commercializes diagnostic products for breast cancer. It develops and commercializes breast CT Imaging system; and 3D CT breast imaging platform for the earlier detection and diagnosis of breast cancer. Th...
How the Company Makes Money
null...
Izotropic Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
9
Very Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Jul 2025 | Jul 2024 | Jul 2023 | Jul 2022 | Jul 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -32.56K | -48.90K | -59.07K | -30.88K | -6.87K | -1.63K |
| EBITDA | -2.37M | -2.14M | -1.60M | -5.33M | -6.63M | -4.97M |
| Net Income | -2.52M | -3.14M | -1.56M | -5.66M | -6.67M | -4.98M |
Balance Sheet | ||||||
| Total Assets | 685.34K | 414.73K | 232.38K | 442.11K | 2.27M | 4.69M |
| Cash, Cash Equivalents and Short-Term Investments | 364.08K | 274.11K | 38.60K | 165.69K | 1.86M | 4.06M |
| Total Debt | 3.14M | 2.76M | 2.06M | 2.14M | 2.03M | 0.00 |
| Total Liabilities | 6.03M | 5.27M | 4.08M | 3.52M | 2.64M | 169.28K |
| Stockholders Equity | -5.34M | -4.86M | -3.85M | -3.07M | -374.59K | 4.52M |
Cash Flow | ||||||
| Free Cash Flow | -961.18K | -637.37K | -593.57K | -3.30M | -4.79M | -3.08M |
| Operating Cash Flow | -961.18K | -636.23K | -593.57K | -3.27M | -4.76M | -3.08M |
| Investing Cash Flow | 0.00 | -1.14K | 0.00 | -36.18K | -24.23K | 0.00 |
| Financing Cash Flow | 1.11M | 872.78K | 468.18K | 1.61M | 2.58M | 6.53M |
Izotropic Technical Analysis
Neutral
0.28
Price Trends
0.22
Positive
0.26
Negative
0.30
Negative
Market Momentum
>-0.01
Negative
52.70
Neutral
53.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Neutral. The current price of 0.28 is above the 20-day moving average (MA) of 0.22, above the 50-day MA of 0.22, and below the 200-day MA of 0.30, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 52.70 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:IZO.
Izotropic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$45.40M | -5.70 | -258.64% | ― | 176.72% | 30.90% | |
50 Neutral | C$23.46M | -5.28 | 106.68% | ― | 28.59% | 23.46% | |
49 Neutral | C$390.25M | -37.02 | ― | ― | 6.82% | -202.55% | |
48 Neutral | C$60.95M | -32.47 | ― | ― | -40.80% | 22.49% | |
44 Neutral | C$21.73M | -15.72 | 53.94% | ― | ― | -7.34% | |
41 Neutral | C$34.31M | -16.88 | -434.25% | ― | ― | 8.62% |
* Healthcare Sector Average
TSE:IZO
Izotropic
0.33
0.10
43.48%
TSE:EDT
Spectral Medical
1.33
0.52
64.20%
TSE:BUX
BioMark Diagnostics
0.58
0.32
123.08%
TSE:PINK
Perimeter Medical Imaging AI
0.36
-0.04
-8.86%
TSE:SONA
Sona Nanotech Inc
0.30
0.01
3.45%
TSE:VPT
VentriPoint Diagnostics
0.13
>-0.01
-3.85%
Izotropic Corporate Events
Business Operations and StrategyProduct-Related Announcements
Izotropic Africa Pursues Moroccan Partnership to Advance Breast CT Expansion
Positive
Feb 25, 2026
Izotropic’s newly formed Casablanca-based venture, Izotropic Africa, is being structured to license, market, and distribute the IzoView Breast CT Imaging System and follow-on products across Africa and the Gulf Cooperation Council, with Izot...
Business Operations and Strategy
Izotropic Moves to Establish African and GCC Hub for Breast CT Imaging
Positive
Feb 18, 2026
Izotropic Corporation has signed a letter agreement with a business group to create Izotropic Africa, a Casablanca-based entity that will license, market, and distribute the IzoView Breast CT system and follow-on products across Africa and the Gul...
Private Placements and Financing
Izotropic Raises Working Capital and Settles Debt with Equity Units
Positive
Feb 4, 2026
Izotropic closed a $300,000 non-brokered private placement by issuing 1.2 million units priced at $0.25, each carrying a share and three-year warrant, with proceeds earmarked for general working capital and contingent on regulatory approvals...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.